Transformable binary-prodrug nanoparticles harness heterogeneity of neutrophils to overcome multidrug resistance and promote pyroptosis in cancer
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Inflammasome and immune disorders · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Neutrophil autophagy and NETosis in COVID-19: perspectives10.1080/15548627.2022.2099206 ↗
2. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-1910.1016/j.chom.2020.12.016 ↗
3. Neutrophils in cancer: heterogeneous and multifaceted10.1038/s41577-021-00571-6 ↗
4. Heterogeneity of neutrophils10.1038/s41577-019-0141-8 ↗
5. Liver tumor immune microenvironment subtypes and neutrophil heterogeneity10.1038/s41586-022-05400-x ↗
6. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy10.1016/j.jconrel.2021.06.027 ↗
7. Neutrophils as emerging immunotherapeutic targets: indirect treatment of tumors by regulating the tumor immune environment based on a sialic acid derivative-modified nanocomplex platform10.1016/j.ijpharm.2022.121684 ↗
8. Neutrophil camouflaged stealth nanovehicle for photothermal-induced tumor immunotherapy by triggering pyroptosis10.1002/advs.202207456 ↗
9. Stimuli-activatable nanomedicine meets cancer theranostics10.7150/thno.87854 ↗
10. The gasdermins, a protein family executing cell death and inflammation10.1038/s41577-019-0228-2 ↗
11. Pyroptosis: mechanisms and diseases10.1038/s41392-021-00507-5 ↗
12. Doxorubicin prodrug-based nanomedicines for the treatment of cancer10.1016/j.ejmech.2023.115612 ↗
13. A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis10.1007/s10787-023-01148-6 ↗
14. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma10.18632/oncotarget.10890 ↗
15. pH-labile artificial natural killer cells for overcoming tumor drug resistance10.1016/j.jconrel.2022.10.042 ↗
16. Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer10.1016/j.actbio.2015.11.031 ↗
17. Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance10.1016/j.ajps.2019.10.003 ↗
18. The expanding role of prodrugs in contemporary drug design and development10.1038/nrd.2018.46 ↗
19. Prodrugs: design and clinical applications10.1038/nrd2468 ↗
20. Enzyme/pH-sensitive polyHPMA-DOX conjugate as a biocompatible and efficient anticancer agent10.1039/C8BM00095F ↗
21. Tumor-pH-sensitive PLLA-based microsphere with acid cleavable acetal bonds on the backbone for efficient localized chemotherapy10.1021/acs.biomac.8b00734 ↗
22. Prodrug approaches for the development of a long-acting drug delivery systems10.1016/j.addr.2023.114860 ↗
23. Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy10.1039/D2CC02267B ↗
24. Disulfide bond reversible strategy enables GSH responsive-transferrin nanoparticles for precise chemotherapy
25. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels
26. Engineering nanomedicine for glutathione depletion-augmented cancer therapy10.1039/D0CS00718H ↗
27. The fate of sialic acid and PEG modified epirubicin liposomes in aged versus young cells and tumor mice models10.3390/pharmaceutics14030545 ↗
28. Sialic acid-mediated photochemotherapy enhances infiltration of CD8+ T cells from tumor-draining lymph nodes into tumors of immunosenescent mice10.1016/j.apsb.2022.06.005 ↗
29. Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity10.1016/j.ijpharm.2021.120552 ↗
30. Cleavable-branched polymer-modified liposomes reduce accelerated blood clearance and enhance photothermal therapy10.1021/acsami.3c02762 ↗
31. Photodynamic/photothermal therapy enhances neutrophil-mediated ibrutinib tumor delivery for potent tumor immunotherapy: more than one plus one?10.1016/j.biomaterials.2021.120652 ↗
32. Tertiary lymphoid structures in cancer10.1126/science.abf9419 ↗
33. Doxorubicin-an agent with multiple mechanisms of anticancer activity10.3390/cells12040659 ↗
34. The role of microRNAs on doxorubicin drug resistance in breast cancer10.1093/jpp/rgaa031 ↗
35. Nanocarriers based on vitamin E-TPGS: design principle and molecular insights into improving the efficacy of anticancer drugs10.1016/j.ijpharm.2020.120045 ↗
36. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy10.1016/j.colsurfb.2018.10.012 ↗
37. Stimuli-responsive, binary-function prodrug encapsulated in hyaluronic acid micelles to overcome doxorubicin resistance10.1016/j.actbio.2021.11.050 ↗
38. Vitamin E enhances cancer immunotherapy by reinvigorating dendritic cells via targeting checkpoint SHP110.1158/2159-8290.CD-21-0900 ↗
39. A smart flower-like polymeric micelle for pH-triggered anticancer drug release10.1016/j.ijpharm.2009.04.005 ↗
40. A novel micellar carrier to reverse multidrug resistance of tumours: TPGS derivatives with end-grafted cholesterol10.1080/1061186X.2023.2205614 ↗
41. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation10.1016/j.ijpharm.2016.10.051 ↗
42. Minimalist nanocomplex with dual regulation of endothelial function and inflammation for targeted therapy of inflammatory vascular diseases10.1021/acsnano.2c11058 ↗
43. Polysialic acid self-assembled nanocomplexes for neutrophil-based immunotherapy to suppress lung metastasis of breast cancer10.1208/s12249-022-02243-7 ↗
44. Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplatforms enhances the efficacy of checkpoint blockade immunotherapy
45. Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation10.1016/j.jconrel.2021.07.044 ↗